Tag: Incretin-Based Drugs Market Shares

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Incretin-Based Drugs Market Value Growth And Long-Term Outlook

The incretin-based drugs market has witnessed substantial expansion in recent years. This market is anticipated to expand from $27.83 billion in 2025 to $29.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The increase observed in the preceding period is attributable to factors such as the widespread prevalence of type 2 diabetes, existing insulin resistance rates, the rise in lifestyle-related metabolic disorders, the greater adoption of endocrinology drugs, and the establishment of hospital diabetes programs.

The incretin-based drugs market is anticipated to experience substantial expansion over the coming years. This market is projected to reach $39.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth stems from factors such as the global obesity epidemic, the increasing demand for weight management drugs, advancements in long-acting incretin innovation, the rise of personalized diabetes care, and a heightened focus on preventive metabolic health. Key developments expected during this period involve the swift embrace of GLP-1 receptor agonists, the broadening of indications for obesity management, a rise in the application of oral incretin therapies, the development of more combination therapy approaches, and enhanced patient adherence due to weekly dosing regimens.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=13362513&type=smp&name=Incretin-Based%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Incretin-Based Drugs Market Expansion Drivers: What’s Shaping Future Growth?

An increasing incidence of type 2 diabetes mellitus is anticipated to significantly boost the expansion of the incretin-based drugs market in the future. This condition is a persistent metabolic ailment marked by the body’s resistance to insulin and reduced insulin production, resulting in elevated blood sugar concentrations. Its widespread occurrence stems from unhealthy dietary habits and a lack of physical activity, which induce insulin resistance, diminishing the body’s capacity to manage blood sugar. Incretin-based medications manage type 2 diabetes by enhancing insulin secretion post-meals and decreasing glucagon output, thereby contributing to lower blood glucose. Furthermore, they extend gastric emptying time and suppress appetite, which assists in glycemic management and contributes to weight reduction. As an illustration, the National Health Service, a UK-based government department, reported in June 2024 that during 2023, approximately 549,000 additional individuals in England were identified as being at risk of developing type 2 diabetes, elevating the total pre-diabetic population to more than 3.6 million, representing a nearly 20% surge from 2022. Consequently, the increasing prevalence of type 2 diabetes mellitus is propelling the growth of the incretin-based drugs market.

Incretin-Based Drugs Market Segment Analysis Spotlighting Growth Areas

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

Incretin-Based Drugs Market Strategic Trends: What Defines The Next Growth Phase?

Companies operating in the incretin-based drugs market are prioritizing the development of generic drug versions to offer more effective and patient-friendly treatment options for type 2 diabetes. A generic drug is a medication that possesses the same active ingredients, strength, dosage form, and route of administration as a brand-name drug, but it is marketed under its chemical name without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product received Food and Drug Administration (FDA) approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, providing a new, more affordable option during ongoing shortages of GLP-1 medications.

Incretin-Based Drugs Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

View The Full Incretin-Based Drugs Market Report:

https://thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Incretin-Based Drugs Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Incretin-Based Drugs Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The incretin-based drugs market has experienced robust expansion over recent years. Projected to increase from $27.83 billion in 2025 to $29.88 billion in 2026, it is advancing at a compound annual growth rate (CAGR) of 7.4%. Historical growth has been driven by the rising prevalence of type 2 diabetes, higher insulin resistance rates, metabolic disorders linked to lifestyle choices, broader adoption of endocrinology medications, and the implementation of hospital-based diabetes initiatives.

The market for incretin-based drugs is projected to experience significant expansion over the coming years, reaching a valuation of $39.25 billion by 2030 with a compound annual growth rate (CAGR) of 7.1%. This anticipated growth in the forecast period is driven by factors such as the global obesity crisis, rising demand for weight management medications, advancements in long-acting incretin formulations, a shift toward personalized diabetes treatments, and an increased emphasis on preventive metabolic health. Key trends shaping this period include the widespread uptake of GLP-1 receptor agonists, the broadening of therapeutic indications to encompass obesity management, a growing preference for oral incretin therapies, the emergence of combination treatment strategies, and enhanced patient compliance facilitated by once-weekly dosing schedules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Incretin-Based Drugs Market Expansion Supported By Key Demand Factors

The anticipated growth of the incretin-based drugs market is being driven forward by the increasing incidence of type 2 diabetes mellitus. This condition, a chronic metabolic disorder marked by insulin resistance and impaired insulin secretion, results in elevated blood glucose levels. Its prevalence stems from poor dietary habits and physical inactivity, which foster insulin resistance and reduce the body’s capacity to regulate blood sugar effectively. Incretin-based drugs address type 2 diabetes by enhancing insulin release following meals and suppressing glucagon production, thereby lowering blood sugar. Additionally, they slow gastric emptying and reduce appetite, contributing to improved glucose control and weight loss. As an illustration, the National Health Service, a UK government department, reported in June 2024 that around 549,000 more people in England were at risk of developing type 2 diabetes in 2023, pushing the total number with pre-diabetes above 3.6 million—a nearly 20% increase from 2022. Consequently, the rising prevalence of type 2 diabetes mellitus is propelling the expansion of the incretin-based drugs market.

Incretin-Based Drugs Market Segmentation Trends And Revenue Drivers

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

Incretin-Based Drugs Market Growth Trends Influencing Competitive Dynamics

Major players in the incretin-based drugs market are now prioritizing the development of generic drug versions to provide patients with more effective and user-friendly treatment options for type 2 diabetes. A generic drug contains identical active ingredients, strength, dosage form, and administration route as its brand-name counterpart, yet it is sold under its chemical name without any brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical firm headquartered in the UK, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product gained approval from the Food and Drug Administration (FDA) and was indicated as a supplement to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. By delivering a fresh and more affordable choice, it addresses the current shortages of GLP-1 medications.

Incretin-Based Drugs Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Access The Complete Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Incretin-Based Drugs Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Incretin-Based Drugs Market Compare Between 2026 And 2030?

The incretin-based drugs market size has experienced robust growth over recent years. This market is anticipated to expand from $27.83 billion in 2025 to $29.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historical market expansion can be linked to factors such as the widespread occurrence of type 2 diabetes, increasing rates of insulin resistance, the rise of lifestyle-related metabolic disorders, the adoption of endocrinology medications, and the implementation of hospital-based diabetes programs.

The incretin-based drugs market is anticipated to expand significantly over the coming years, with its size projected to reach $39.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected expansion during the forecast period stems from factors such as the global rise in obesity, the increasing need for weight management medications, breakthroughs in long-acting incretin therapies, the move towards individualized diabetes treatment, and a greater emphasis on proactive metabolic health. Key developments expected during this period involve the swift embrace of GLP-1 receptor agonists, broader applications for obesity management, a rise in the utilization of oral incretin treatments, the emergence of more combination therapy strategies, and enhanced patient compliance through once-weekly dosing regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Drivers Are Advancing The Incretin-Based Drugs Market Growth?

The expanding occurrence of type 2 diabetes mellitus is projected to stimulate the growth of the incretin-based drugs market in the coming years. This chronic metabolic condition is defined by insulin resistance and impaired insulin secretion, resulting in elevated blood glucose levels. The increase in type 2 diabetes is attributed to factors like poor diet and insufficient physical activity, which contribute to insulin resistance and hinder the body’s ability to regulate blood sugar. Incretin-based drugs work by enhancing insulin release after meals and lowering glucagon production, thereby assisting in blood sugar reduction. They further contribute to glucose control and weight management by delaying gastric emptying and suppressing appetite. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, about 549,000 more people in England were at risk of developing type 2 diabetes, increasing the total number with pre-diabetes to over 3.6 million, marking a nearly 20% rise from 2022. Thus, the escalating prevalence of type 2 diabetes mellitus is a key factor propelling the expansion of the incretin-based drugs market.

Which Segment Divisions Form The Structure Of The Incretin-Based Drugs Market?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Trends Are Driving Changes In The Incretin-Based Drugs Market?

Leading companies in the incretin-based drugs market are prioritizing the development of generic drug versions to offer more effective and convenient treatment options for type 2 diabetes. A generic drug is a medication that shares the same active ingredients, strength, dosage form, and method of administration as a brand-name drug, but is commercialized under its chemical name without brand identification. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical firm, launched the initial generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product gained approval from the Food and Drug Administration (FDA). It is indicated as an addition to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst ongoing shortages of GLP-1 medications.

Which Key Players Are Active In The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Access The Complete Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Accounts For The Highest Share Of The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Incretin-Based Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Incretin-Based Drugs Market Projected To Reach By 2030?

The incretin-based drugs market has experienced substantial growth in recent years. It is projected to increase from $27.83 billion in 2025 to $29.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. This expansion during the historic period can be attributed to factors such as the prevalence of type 2 diabetes, insulin resistance rates, lifestyle-related metabolic disorders, the adoption of endocrinology drugs, and hospital diabetes programs.

The incretin-based drugs market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is attributable to factors such as the global obesity epidemic, the increasing demand for weight management drugs, advancements in long-acting incretin therapies, a shift towards personalized diabetes care, and an emphasis on preventive metabolic health. Key trends expected over the forecast period encompass the swift uptake of GLP-1 receptor agonists, the broadening of obesity management indications, an increase in the application of oral incretin therapies, the emergence of more combination therapy approaches, and enhanced patient adherence facilitated by weekly dosing regimens.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Factors Are Influencing The Growth Of The Incretin-Based Drugs Market?

The escalating occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market. This chronic metabolic condition is characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. The widespread incidence of Type 2 diabetes is primarily attributed to poor dietary choices and sedentary lifestyles, which contribute to insulin resistance and diminish the body’s ability to regulate blood sugar. Incretin-based drugs offer a therapeutic approach for type 2 diabetes by enhancing insulin release after meals and decreasing glucagon production, thereby helping to reduce blood sugar. These medications also slow stomach emptying and curb appetite, assisting in glucose control and weight loss. For example, in June 2024, the National Health Service, a UK-based government department, stated that in 2023, about 549,000 more people in England faced a risk of developing type 2 diabetes, pushing the total number with pre-diabetes to over 3.6 million, marking a nearly 20% increase from 2022. Thus, the increasing prevalence of type 2 diabetes mellitus is a key factor stimulating the growth of the incretin-based drugs market.

Which Segment Types Are Examined In The Incretin-Based Drugs Market Segment Study?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Trends Are Transforming The Incretin-Based Drugs Market?

Leading companies active in the incretin-based drugs market are prioritizing the development of generic drug versions to supply more effective and patient-friendly therapeutic options for type 2 diabetes. A generic medication possesses the identical active constituents, strength, dosage format, and administration route as a branded drug, but it is distributed under its chemical identity without brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched the inaugural generic variant of Victoza (liraglutide) injection, 6 mg/mL, in the United States. It obtained Food and Drug Administration (FDA) approval. The product was indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst current shortages of GLP-1 medications.

Which Players Are Part Of The Competitive Landscape Of The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Get The Full Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Leads The Incretin-Based Drugs Market In Overall Market Size?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Incretin-Based Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Incretin-Based Drugs Market Evolve From 2026 To 2030?

The incretin-based drugs market size has experienced robust growth in recent years. It is projected to expand from $27.83 billion in 2025 to $29.88 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. Historically, this growth can be attributed to the prevalence of type 2 diabetes, insulin resistance rates, lifestyle-related metabolic disorders, the adoption of endocrinology drugs, and various hospital diabetes programs.

The incretin-based drugs market size is projected to experience robust expansion over the coming years. Its value is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period stems from factors such as the worldwide obesity epidemic, the increasing need for weight management medications, advancements in long-acting incretin therapies, customized diabetes treatment, and a greater emphasis on preventive metabolic health. Key trends anticipated in this period encompass the swift uptake of GLP-1 receptor agonists, the broadening of indications for obesity management, a rise in the application of oral incretin therapies, the development of more combination therapy strategies, and enhanced patient compliance due to weekly dosing.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

What Drivers Are Influencing The Incretin-Based Drugs Market?

The increasing occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market in the future. Type 2 diabetes mellitus, a long-term metabolic condition, is marked by resistance to insulin and reduced insulin secretion, resulting in high blood glucose levels. This condition’s rise is linked to unhealthy eating habits and lack of physical activity, which lead to insulin resistance and hinder the body’s ability to manage blood sugar. Incretin-based drugs address type 2 diabetes by stimulating insulin release post-meal and decreasing glucagon production, thereby assisting in lowering blood sugar. These drugs also slow gastric emptying and suppress hunger, contributing to better glucose management and weight reduction. A relevant example shows that in June 2024, the National Health Service, a UK government body, reported that approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes in 2023, elevating the total pre-diabetes population to over 3.6 million, marking a nearly 20% surge from 2022. Consequently, the growing prevalence of type 2 diabetes mellitus is fueling the growth of the incretin-based drugs market.

Which Segment Areas Are Covered In The Incretin-Based Drugs Market Analysis?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Key Developments And Trends Are Impacting The Incretin-Based Drugs Market?

Major companies within the incretin-based drugs market are concentrating on developing generic drug alternatives to provide more effective and patient-friendly treatment options for type 2 diabetes. A generic medication shares the same active ingredients, strength, dosage form, and administration route as a brand-name drug but is marketed under its chemical name without brand labeling. For example, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product received approval from the Food and Drug Administration (FDA). It is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a new, more affordable alternative amidst ongoing shortages of GLP-1 medications.

Which Global Companies Are Actively Competing In The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Read the full incretin-based drugs market report here:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Incretin-Based Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the incretin-based drugs market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Incretin-Based Drugs Market?

The incretin-based drugs market has witnessed significant expansion in recent years. Its value is anticipated to rise from $27.83 billion in 2025 to $29.88 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. This historical growth can be linked to factors such as the increasing prevalence of type 2 diabetes, higher rates of insulin resistance, the rise in lifestyle-related metabolic disorders, broader adoption of endocrinology drugs, and various hospital diabetes programs.

The incretin-based drugs market is projected for robust expansion in the coming years. It is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period stems from factors such as the global obesity epidemic, rising demand for weight management drugs, advancements in long-acting incretin formulations, the emphasis on personalized diabetes care, and a greater focus on preventive metabolic health. Key trends anticipated over this period encompass the swift uptake of GLP-1 receptor agonists, the broadening of indications for obesity management, an increased prevalence of oral incretin therapies, the development of more combination therapy strategies, and enhanced patient adherence facilitated by weekly dosing regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Drivers Are Supporting The Rise Of The Incretin-Based Drugs Market?

The incretin-based drugs market is anticipated to expand due to the increasing occurrence of type 2 diabetes mellitus. This chronic metabolic condition is marked by insulin resistance and reduced insulin secretion, resulting in high blood glucose. Poor diet and lack of physical activity contribute to insulin resistance, making it harder for the body to manage blood sugar levels. Incretin-based drugs address type 2 diabetes by enhancing insulin secretion after meals and decreasing glucagon production, thereby lowering blood sugar. They also slow gastric emptying and suppress appetite, which assists in blood glucose management and weight loss. For example, in June 2024, the National Health Service reported that in 2023, approximately 549,000 additional individuals in England faced a risk of developing type 2 diabetes, pushing the total number with pre-diabetes to over 3.6 million, an increase of nearly 20% compared to 2022. Consequently, the growing incidence of type 2 diabetes mellitus is a key factor propelling the incretin-based drugs market.

What Leading Segments Are Studied In The Incretin-Based Drugs Market?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Trends Are Driving The Growth Trajectory Of The Incretin-Based Drugs Market?

Companies operating significantly within the incretin-based drugs market are prioritizing the development of generic drug alternatives to provide more effective and convenient treatment choices for individuals with type 2 diabetes. A generic medication is characterized by possessing identical active ingredients, strength, dosage form, and administration route as its brand-name counterpart, yet it is marketed under its chemical designation without any brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical firm based in the UK, introduced the initial generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product secured approval from the Food and Drug Administration (FDA). It is prescribed as an addition to diet and exercise for enhancing glycemic control in adults and pediatric patients aged 10 years and older diagnosed with type 2 diabetes, thereby offering a fresh, more economical solution amidst current scarcities of GLP-1 medications.

Which Major Firms Are Strengthening Their Position In The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Incretin-Based Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Incretin-Based Drugs Market By 2029?

The incretin-based drugs market has experienced substantial growth in recent years. Its value is expected to rise from $25.89 billion in 2024 to $27.83 billion in 2025, at a compound annual growth rate (CAGR) of 7.5%. This historical expansion can be attributed to several factors, including the increasing global prevalence of type 2 diabetes, the introduction of GLP-1 receptor agonists such as exenatide and liraglutide, considerable investments in research and development, advantageous regulatory approvals for DPP-4 and GLP-1 drugs, a shift away from insulin and sulfonylureas towards newer classes of medication, and the availability of once-weekly injectable formulations.

The incretin-based drugs market size is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $36.7 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the projection period stems from several factors, including the rising acceptance of fixed-dose combination treatments, an increased emphasis on weight control and diabetes associated with obesity, advancements in personalized medicine and companion diagnostics, a heightened need for less invasive drug delivery methods, and an expanding elderly demographic facing a greater prevalence of comorbidities. Key trends anticipated during this forecast encompass the incorporation of incretin pharmaceuticals into strategies for obesity management, the emergence of dual and triple agonists designed to improve metabolic results, the fusion of digital health solutions with incretin therapies for tailored oversight, the increasing prevalence of combination therapies over monotherapy for sophisticated diabetes regulation, and an emphasis on long-acting weekly injections to ease the frequency of administration.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

What Are The Key Drivers Of Growth In The Incretin-Based Drugs Market?

The increasing occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market moving ahead. This condition is a persistent metabolic ailment marked by the body’s resistance to insulin and reduced insulin production, resulting in elevated blood sugar levels. Its widespread occurrence stems from unhealthy eating habits and lack of physical activity, which contribute to insulin resistance, thereby diminishing the body’s capacity to manage blood sugar effectively. Incretin-based drugs address type 2 diabetes by stimulating insulin secretion following meals and decreasing glucagon output, which assists in lowering blood sugar. Additionally, these medications postpone gastric emptying and suppress hunger, facilitating better glucose management and weight reduction. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes, bringing the total number with pre-diabetes to more than 3.6 million, marking a nearly 20% increase from 2022. Consequently, the growing incidence of type 2 diabetes mellitus is fueling the expansion of the incretin-based drugs market.

How Is The Incretin-Based Drugs Market Segmented?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Are The Latest Industry Trends Transforming The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are increasingly focusing on the development of generic drug versions to offer more effective and patient-friendly treatment options for type 2 diabetes. A generic drug is a medication that possesses the same active ingredients, strength, dosage form, and route of administration as a brand-name drug, but is commercially sold under its chemical designation without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, within the United States. This product received Food and Drug Administration (FDA) approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, thereby furnishing a new, more affordable option amidst ongoing shortages of GLP-1 medications.

Which Major Firms Are Strengthening Their Position In The Incretin-Based Drugs Industry?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2025, By The Business Research Company

Null 2025

NULL

Hybrid Valve Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hybrid-valve-global-market-report

Hybrid Composites Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hybrid-composites-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Incretin-Based Drugs Market Heading Into 2029?

In recent years, the market size for incretin-based drugs has impressively expanded. It’s expected to rise from a worth of $25.89 billion in 2024 to a projected $27.83 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.5%. This significant growth during the historical period can be linked to numerous factors. These include the growing incidence of type 2 diabetes worldwide and the launch of GLP-1 receptor agonists like exenatide and liraglutide. Additionally, the inflow of research and development investments, the approval favorable from regulatory bodies for DPP-4 and GLP-1 drugs, the shift from insulin and sulfonylureas to more modern drug classes, and the emergence of injectable formulations available once a week have all further fueled this surge.

The market for incretin-based drugs is set for significant expansion in the coming years, swelling to a sizable $36.7 billion by 2029 with a compound annual growth rate (CAGR) of 7.2%. This anticipated growth within the predicted period is likely due to a rising inclination towards fixed-dose combination therapies, an amplified emphasis on weight management and diabetes connected to obesity, advancements in personalized medicine and accompaniment diagnostics, growing demand for minimally invasive delivery techniques for drugs, as well as a rising aged population with higher comorbidity complications. Important trends emerging within this period encompass the usage of incretin drugs within obesity management programs, the emergence of dual and triple agonists to boost metabolic results, the incorporation of digital health into incretin treatments for individual monitoring, the dominance of combination treatments over monotherapy for improved diabetes regulation, and a focus on long-lasting weekly injections for the reduction of dosing burden.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Factors Are Pushing The Incretin-Based Drugs Market Forward?

The incretin-based drugs market is anticipated to grow due to the increasing prevalence of type 2 diabetes mellitus. This chronic metabolic disorder, featuring insulin resistance and deficient insulin secretion, escalates levels of glucose in the blood. The occurrence of Type 2 diabetes is commonly linked to poor nutrition and lack of physical activity which causes insulin resistance, thus negatively affecting the body’s ability to regulate blood sugar levels. Incretin-based medications improve this type of diabetes by elevating insulin release post-meal, reducing glucagon production, and therefore, lowering blood sugar. These drugs also slow down stomach emptying and suppress appetite, which aids in glucose management and weight loss. For instance, the National Health Service, a government department in the UK, stated in June 2024 that in 2023, approximately 549,000 more individuals in England were at risk of developing type 2 diabetes. This brought the total number of pre-diabetic individuals to over 3.6 million, which is almost a 20% rise from 2022. Consequently, due to the escalating prevalence of type 2 diabetes mellitus, the incretin-based drugs market is witnessing growth.

Which Segment Held The Largest Share In The Incretin-Based Drugs Market In 2025?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

How Are Key Trends Driving Expansion In The Incretin-Based Drugs Industry?

Key players in the incretin-based drugs market are striving to create a generic version of drugs as a more potent and user-friendly treatment solution for type 2 diabetes. A generic drug contains equivalent active ingredients, strength, dosage form, and administration path as a branded drug, but it is sold under its chemical name without the branding. To illustrate, Hikma Pharmaceuticals PLC, a pharmaceutical company from the UK, introduced the first generic version of Victoza, which is a liraglutide injection of 6 mg/mL, in America in December 2024. The Food and Drug Administration (FDA) gave its approval. It was specified to be used as a supplementary measure to diet and exercise for better glycemic control in adults and children aged 10 or above who have type 2 diabetes. It thus offers a fresh and more economical alternative at a time when GLP-1 medications are in scarce supply.

Which Organizations Are Driving Progress In The Incretin-Based Drugs Industry?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Incretin-Based Drugs Industry?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Incretin-Based Drugs Market?

In recent times, the market size of incretin-based drugs has seen sturdy growth. With a compound annual growth rate (CAGR) of 7.5%, it’s projected to escalate from $25.89 billion in 2024 to $27.83 billion in 2025. This substantial growth during the historical phase is credited to the worldwide increase in type 2 diabetes instances, the launch of GLP-1 receptor agonists such as exenatide and liraglutide, substantial investments in research and development, favorable regulatory green lights for DPP-4 and GLP-1 drugs, a transition from insulin and sulfonylureas to newer categories of drugs, and the availability of once-weekly injectable formulations.

What Growth Rate Is Forecasted for the Incretin-Based Drugs Market by 2029?

In the forthcoming years, the market for incretin-based drugs is predicted to experience significant growth, with a projected value of $36.7 billion in 2029, corresponding to a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is primarily due to factors such as the increased preference for fixed-dose combination therapies, a growing emphasis on weight management and obesity-related diabetes, advancement in personalized medicine and companion diagnostics, rising demand for minimally invasive drug delivery technologies, and an aging population with a greater comorbidity burden. During this forecast period, key trends that are expected to emerge include the incorporation of incretin medications into obesity control protocols, development of dual and triple agonists to boost metabolic outcomes, digital healthcare integration with incretin treatments for personalized supervision, dominance of combination therapy over monotherapy in the management of advanced diabetes, and increased attention towards long-lasting weekly injections to minimize the dosing load.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Key Companies Are Shaping the Future of the Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Which Factors Are Driving Demand in the Incretin-Based Drugs Industry?

An increasing number of type 2 diabetes mellitus cases is predicted to fuel the expansion of the market for incretin-based drugs. Characterized by insulin resistance and failing insulin secretion, type 2 diabetes mellitus is a chronic metabolic disorder that results in increased blood glucose levels. The rise in Type 2 diabetes cases can be attributed to poor dietary habits and lack of physical activity, which lead to insulin resistance and hinder the body’s capacity to control blood sugar levels. Incretin-based medications offer a remedy by amplifying insulin release post meals, reducing the production of glucagon, and assisting in decreasing blood sugar levels. These drugs also slow down digestion, suppress appetite, and by doing so aid in glucose regulation and weight loss. For example, the National Health Service, a UK government department, stated in June 2024 that approximately 549,000 more individuals in England were at risk of developing type 2 diabetes in 2023. This spiked the total number of people with pre-diabetes to over 3.6 million, marking nearly a 20% increase from 2022. Due to these reasons, the increasing occurrence of type 2 diabetes mellitus is contributing to the growth of the incretin-based drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

How Is the Incretin-Based Drugs Market Segmented by Several Divisions?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What are the Emerging Market Trends Driving the Growth of the Incretin-Based Drugs Industry?

Key players in the incretin-based drugs market are striving to create generic versions of drugs, aiming to deliver more efficient and patient-centric treatments for type 2 diabetes. A generic drug bears the same active ingredients, strength, method of administration, and dosage form as its branded counterpart, but is marketed by its chemical name instead of a brand. For example, in December 2024, the UK-based Hikma Pharmaceuticals PLC introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the US, following FDA approval. This marked it as a supplementary treatment, along with diet and exercise, to better regulate blood sugar levels in adults and children above 10 years dealing with type 2 diabetes, thereby presenting a cost-effective alternative amidst the ongoing scarcity of GLP-1 medications.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Regions Are Driving Growth in the Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24570

This Report Delivers Insight On:

1. How big is the incretin-based drugs market, and how is it changing globally?

2. Who are the major companies in the incretin-based drugs market, and how are they performing?

3. What are the key opportunities and risks in the incretin-based drugs market right now?

4. Which products or customer segments are growing the most in the incretin-based drugs market?

5. What factors are helping or slowing down the growth of the incretin-based drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model